2016
DOI: 10.1097/fbp.0000000000000208
|View full text |Cite
|
Sign up to set email alerts
|

Brain catechol-O-methyltransferase (COMT) inhibition by tolcapone counteracts recognition memory deficits in normal and chronic phencyclidine-treated rats and in COMT-Val transgenic mice

Abstract: The critical involvement of dopamine in cognitive processes has been well established, suggesting therapies targeting dopamine metabolism may alleviate cognitive dysfunction. COMT is a catecholamine-degrading enzyme, the substrates of which include dopamine, epinephrine, and norepinephrine. The present work illustrates the potential therapeutic efficacy of COMT inhibition for alleviating cognitive impairment. A brain penetrant COMT inhibitor, tolcapone, was tested in normal and phencyclidine (PCP)-treated rats… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

1
13
0

Year Published

2017
2017
2023
2023

Publication Types

Select...
8

Relationship

1
7

Authors

Journals

citations
Cited by 16 publications
(14 citation statements)
references
References 33 publications
1
13
0
Order By: Relevance
“…Moreover, we only used a single strain (C57BL/6J), so our results may also be strain-specific. We chose C57BL/6J mice because they are a commonly used strain for behavioral studies and many of the mutant models we use in our laboratory are on a C57BL/6J background (Carr et al, 2016Detrait et al, 2016.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…Moreover, we only used a single strain (C57BL/6J), so our results may also be strain-specific. We chose C57BL/6J mice because they are a commonly used strain for behavioral studies and many of the mutant models we use in our laboratory are on a C57BL/6J background (Carr et al, 2016Detrait et al, 2016.…”
Section: Discussionmentioning
confidence: 99%
“…We dosed tolcapone at 3, 10, and 30 mg/kg. The 30 mg/kg dose has been shown to modulate behavior in both mice and rats in multiple assays (Tunbridge et al, 2004;Lapish et al, 2009;Detrait et al, 2016). Additionally, the exposure levels at 30 mg/kg dose produce over 90% inhibition of COMT activity in rats in vivo (Napolitano et al, 2003).…”
Section: Drugsmentioning
confidence: 99%
“…The enzyme coding region contains a well-investigated single-nucleotide-polymorphism (SNP) in codon 158 (rs4680), in which valine (Val) is substituted to methionine (Met) through a substitution of guanine to adenine. This common functional A/G polymorphism in the COMT gene produces three genotype groups (homozygousVal158Val, heterozygous Val158Met, and homozygous Met158Met), which result in different enzyme activities based on changes in thermostability [ 11 , 12 ] as depicted in Table 1 . The three phenotypes of the COMT enzyme activities include COMT A/A with low enzyme activity, COMT A/G with medium enzyme activity and COMT G/G with high enzyme activity.…”
Section: Introductionmentioning
confidence: 99%
“…7), and its selectivity towards the membrane-bound form of catechol-o-methyl transferase (MB-COMT) compared with its water-soluble form (S-COMT) [146]. The COMT inhibitors are used together with L-dopa in the treatment of Parkinson's disease to prevent dopamine deficit [147,148]. L-Dopa is converted into dopamine inside the neurons, and the role of COMT inhibitors in the drug formulation is to prevent L-dopa degradation.…”
Section: The Effect Of Membrane Sorting For Drugs and Beyondmentioning
confidence: 99%